Latest News Releases Keyword Search Year None20242023202220212020201920182017201620152014201320122011201020092008200720062005200420032002200120001999199819971996 5/9/24 Neurocrine Biosciences Presents CAHtalyst™ Adult Study Baseline Characteristics and Data on Impact of Supraphysiologic Glucocorticoid Therapy at AACE 2024 5/9/24 Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1076986 in Healthy Adults 5/8/24 Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1117567 in Healthy Adults 5/7/24 Neurocrine Biosciences to Present at the BofA Securities 2024 Health Care Conference 5/7/24 Neurocrine Biosciences to Present Phase 3 Baseline Characteristics Data from the CAHtalyst™ Program of Crinecerfont in CAH, and Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH Studies at ECE 2024 5/6/24 Neurocrine Biosciences Supports Tardive Dyskinesia Awareness Week by Advocating for Routine Screening and Monitoring 5/3/24 Neurocrine Biosciences Presented CAHtalyst™ Pediatric Study Baseline Characteristics and CAHtalog™ Registry Data at PES 2024 5/1/24 Neurocrine Biosciences Reports First Quarter 2024 Financial Results 4/30/24 Neurocrine Biosciences Announces U.S. FDA Approval of INGREZZA® SPRINKLE (valbenazine) Capsules 4/24/24 Neurocrine Biosciences Launches WHAT THE C@H?! Educational Initiative to Support Congenital Adrenal Hyperplasia Community 4/23/24 Neurocrine Biosciences Reports Positive Phase 2 Data for NBI-1065845 in Adults with Major Depressive Disorder 4/10/24 Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2024 Financial Results 4/3/24 Neurocrine Biosciences Announces First-Patient Dosed in Phase 2 Clinical Study Evaluating NBI-1070770 in Adults with Major Depressive Disorder 3/28/24 Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1065890, a Second-Generation VMAT2 Inhibitor, in Healthy Adults 3/11/24 Neurocrine Biosciences to Participate at Virtual Investor Conferences in March 2/27/24 Neurocrine Biosciences to Participate at Investor Conferences in March 2/7/24 Neurocrine Biosciences Reports Fourth Quarter and Fiscal 2023 Financial Results and Provides Financial Expectations for 2024 1/17/24 Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2023 Financial Results 1/2/24 Neurocrine Biosciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference